|
gptkbp:instanceOf
|
medical intervention
|
|
gptkbp:abbreviation
|
gptkb:PrEP
|
|
gptkbp:administeredBy
|
HIV-negative individuals
|
|
gptkbp:alternativeTo
|
long-acting injectable
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:category
|
HIV/AIDS prevention
preventive medicine
public health intervention
|
|
gptkbp:commonDrug
|
emtricitabine
tenofovir
|
|
gptkbp:contraindication
|
severe renal impairment
HIV-positive status
|
|
gptkbp:effect
|
over 90% with high adherence
|
|
gptkbp:frequency
|
daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pre-Exposure Prophylaxis
|
|
gptkbp:involves
|
antiretroviral drugs
|
|
gptkbp:longActingDrug
|
gptkb:cabotegravir
|
|
gptkbp:recommendation
|
gptkb:CDC
|
|
gptkbp:reduces
|
HIV infection
|
|
gptkbp:requires
|
medical follow-up
regular HIV testing
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
renal impairment
|
|
gptkbp:targetAudience
|
gptkb:men_who_have_sex_with_men
people who inject drugs
heterosexual individuals at high risk
|
|
gptkbp:usedFor
|
HIV prevention
|
|
gptkbp:bfsParent
|
gptkb:PrEP
|
|
gptkbp:bfsLayer
|
6
|